Extrait 5 ( PDF 1 539 Ko)
|
Preliminary Data Report on a Phase 1/2A First in Human Study
KO-539 is a potent and selective inhibitor of the Menin-KMT2A (MLL) complex KO-539 demonstrates early encouraging clinical activity in different genomic subgroups KO-539 has been well tolerated and with a manageable safety profile to date Plasma KO-539 exposure increases with dose |
|
A novel small molecule menin-MLL inhibitor for potential
Oct 18 2017 · Here we report that KO-539 is highly effective in two independent models of MLL wild-type AML displaying robust and persistent antitumor activity when dosed orally daily at well-tolerated doses Conclusions • KO-539 is a potent selective small molecule menin -MLL inhibitor designed for therapy of MLL-rearranged AML but |
|
Activity of menin inhibitor ziftomenib (KO-539) as
-1 5-1 0-0 5 0 G PD mtNPM1 +FLT3-TKD #6 BCL2 Bcl-xL BIM CDK6 HOXA9 Ki67 MDM2 MEF2C Meis1 Menin PBX3 RUNX1 F old-cha n ge (z iftome n i b /Co n t rol) 16 hrs PD AML Stem Cells Defined by: CLEC12A |
Does co-administration of a CYP3A4 inhibitor affect plasma ko-539 exposure?
KO-539 has been well tolerated and with a manageable safety profile to date Plasma KO-539 exposure increases with dose KO-539 pharmacokinetics and clinical activity do not appear to be affected by co-administration of an CYP3A4 inhibitor
Does co-administration of komet-001 affect plasma ko-539 exposure?
Plasma KO-539 exposure increases with dose KO-539 pharmacokinetics and clinical activity do not appear to be affected by co-administration of an CYP3A4 inhibitor KOMET-001 is continuing to enroll patients for phase 1 dose escalation, with plans to expand to phase 2 once recommended phase 2 dose is determined
Does ko-539 induce differentiation and loss of viability in PDX models?
Preclinical data show that KO-539 and close analogs induce differentiation and loss of viability of AML cells, and exert profound anti-leukemic activity in multiple PDX models harboring MLL-FP or NPM1c when dosed continuously QD for 3-6 weeks.
How is ko-539 metabolized?
KO-539 is metabolized into at least two metabolites with comparable activity to KO-539; total drug concentrations (i.e., KO-539 plus active metabolites) exhibited a dose-dependent increase.
|
TITULO PENDIENTE DE IDENTIFICAR 5 AM 1 02 002 2 03 3 4 5 7 8
60 539 N 101 53 40 E. 60 DIAS DEL SOFA 690 201502. 60 DIAS DEL SOFA 700 201502. 60 MINUTES. 60 MINUTES MIX BBC 1XCTA. 60 MONOS. 60 SECONDS TO WHAT. |
|
Palaeohispanica 5 (2005). Acta Palaeohispanica IX. Actas del IX
REVISTA SOBRE LENGUAS Y CULTURAS. DE LA HISPANIA ANTIGUA. 5 Pervivencia de la lengua ibérica en el siglo I a.C. El ejemplo de. |
|
Tesis Doctoral Sobre los sueños de Aristóteles Doctorando: D
In all the research and especially in chapter 5 ('The vocabulary of sleep Cf. KIRK & RAVEN |
|
Estructura del comportamiento humano en Camus
(1 0 ) |
|
Bibliographie sur lhistoire de la Compagnie de Jésus
Rom de la reproducción en PDF de las bibliografías anuales sobre 537-539. INDEX DES AUTEURS. 540-551 ... Theologica et historica 5 (1996) 127-150. |
|
Lírica popular de primera persona femenina principalmente en
Hablamal del amigo: 5.4.1. Insulto. 475-483. 54.2. Escarnio. 484-539 Extrait de la Revue ... Nafarrca-ko Huskal-kantu Zaharrak <Viejas canciones. |
|
Comirnaty Common name: COVID-19 mRNA vaccine (nucleoside
21 dic 2020 1 * Correction dated 19 February 2021 to clarify ERA statement ... 2.2.5. Conclusions on the chemical pharmaceutical and biological aspects ... |
|
Chapitre 1 - Techniques dexamen
Grille d'Amsler 5. Test de comparaison de l'intensité de la lumière 6. Test de photostress 6. Évaluation de la vision des couleurs 7. |
|
RÈGLEMENT (CE) No 1295/2008 DE LA COMMISSION du 18
18 dic 2008 L'article 158 paragraphe 1 |
|
Argitalpen jardueraren katalogoa [1918-1998 - Eusko Ikaskuntza
1 4 5. 11 . 2 . 5 . Eusko Ikaskuntza-Euskadiko Kutxaren Giza eta Gizarte Fuentes documentales medievales del País Vasco (Euskal Herriko Erdi Aro k o. |
|
Interprime 539 - AkzoNobel Marine Coatings
4 fév 2015 · Extrait-Sec Volumique Epaisseur recommandée Pouvoir couvrant théorique Méthode d'application Aspect / Brillance Mat (ISO 2813:1978) |
|
INTERNATIONAL Interprime 539 - Arc O Paint
Teinte Jaune, rose Aspect Mat Extrait sec en Volume 24 Epaisseur Recommandée 10-20 microns (0,4-0,8 mils) de film sec pour 42-83 microns (1,7- 3,3 |
|
CODE PENAL - ILO
ou par extraits dans un ou plusieurs journaux qu'elle désigne ou sera affichée dans les lieux qu'elle indique, le tout aux frais du condamné, sans toutefois que |
|
IRC volume 45 issue 539 Cover and Back matter
L'OVOMALTINE contient toutes les substances con- structives naturelles qui sont necessaires a I'orga- nisme: extrait de malt (orge germ6e), lait complet, |
|
Treaty Series Recueil des Traites - United Nations Treaty Collection
Nations Unies, Recueil des Traitis, vol 538, no 7818 Vol 539-2 par la voie diplomatique, d'un bulletin ou extrait de condamnation au gouverne- ment du pays |
|
Extrait de Résolution CV-2019-0098 - Ville de Québec
des lots numéros 1 216 765, 1 539 384, 1 539 437, 1 539 438, 5 915 200 et 5 915 201 du cadastre du Québec, R A V Q 1244 - PA2019-003 (Ra- 2102) |
|
Extrait de Résolution CAAM-2019-0055 - Ville de Québec
réalisation d'un projet de terminus d'autobus et d'un stationnement incitatif sur la partie du territoire formée des lots numéros 1 216 765, 1 539 384, 1 539 437, |
|
CODE DE COMMERCE
15 nov 2012 · Un extrait de cet acte est inscrit au registre du commerce 73- Les dispositions de l'alinéa 2 de l'article 538, 539, 541, 542 ont été modifiées |
